TVRD: Cara Therapeutics Inc Company Short-Term Debt
Cara Therapeutics Inc (TVRD) is developing therapies for kidney pathologies while adhering to environmental regulations regarding chemical waste recycling. The market trend for short-term debt value stands at 0.00. Due to the failure of primary clinical trials, Cara Therapeutics Inc (TVRD) has scaled back activity and stalled business growth, focusing on aggressive reductions in administrative expenses to protect remaining cash reserves.
Summary analytical data breakdowns for Cara Corp (TVRD)
The indicator's dynamics depend directly on the balance between current operating cash flows and short-term liabilities. This metric captures the aggregate of all credit claims with a repayment horizon of up to twelve months. For Cara Therapeutics Inc (TVRD), such borrowings may fund joint development projects with Vifor Pharma to create medications for renal pruritus. Effective liquidity management minimizes default risk, while monitoring current debt allows for an assessment of the company's capacity to meet its payment obligations.